Menu
Close
Primary links
Newsroom Home
Press Releases
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
Biosimilars
Collaborations
Events & Webcasts
Sign up for Alerts
All Press Releases
Login
All Press Releases
Filter by
<Any>
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
-Year
2009
2010
2011
2012
2013
2014
2015
2016
2017
Search
Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017
9/26/17 4:01 pm EDT
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
9/6/17 4:01 pm EDT
Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
7/25/17 6:30 am EDT
Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017
6/20/17 4:01 pm EDT
SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
6/1/17 7:30 am EDT
Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
5/31/17 5:00 pm EDT
Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
5/17/17 4:01 pm EDT
Biogen Reports First Quarter 2017 Revenues of $2.8 Billion
4/25/17 6:59 am EDT
Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
4/24/17 7:30 am EDT
Biogen to Report First Quarter 2017 Financial Results on April 25, 2017
3/27/17 4:01 pm EDT
1
2
next ›
last »
Investor Relations Press Releases
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017
9/26/17 4:01 pm EDT
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
9/6/17 4:01 pm EDT
Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
7/25/17 6:30 am EDT
Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017
6/20/17 4:01 pm EDT
SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
6/1/17 7:30 am EDT
Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
5/31/17 5:00 pm EDT
Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
5/17/17 4:01 pm EDT
Biogen Reports First Quarter 2017 Revenues of $2.8 Billion
4/25/17 6:59 am EDT
Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
4/24/17 7:30 am EDT
Biogen to Report First Quarter 2017 Financial Results on April 25, 2017
3/27/17 4:01 pm EDT
1
2
next ›
last »
